Eprosartan: An angiotensin-II receptor antagonist for the management of hypertension

Heart Disease

Volumn 4, Issue 1, 2002, Pages 54-59

  Cheng Lai, Angela ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CANDESARTAN HEXETIL; DIGOXIN; EPROSARTAN; FLUCONAZOLE; GLUCURONIDE; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; PLACEBO; RIFAMPICIN; TELMISARTAN; VALSARTAN;

CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT;

EID: 0036270863     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200201000-00010     Document Type: Review

References (28)

1. Eprosartan. A review of its use in the management of hypertension
2. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker
3. Clinical efficacy of eprosartan
4. Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data
5. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations
6. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists
7. Effect of age and gender on the pharmacokinetics of eprosartan
8. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan
9. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and patients with varying degrees of renal impairment
10. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease
11. Efficacy and safety of eprosartan in patients with essential hypertension: Results of an 8-week, double-blind, placebo-controlled, multicenter trial
12. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension
13. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension
14. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients
15. Efficacy and safety of eprosartan in severe hypertension
16. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: Subgroup analysis of a 26 week, double-blind, multicentre study
17. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study
18. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension
19. Safety and tolerability of eprosartan
20. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies
21. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin n healthy male volunteers
22. Eprosartan does not affect the pharmacodynamics of warfarin
23. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus
24. Effect offluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
25. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers
26. Management of difficult to control hypertension
27. Is it time for a new approach to the initial treatment of hypertension?